$20.70
(Market cap
$-- Mln
Revenue (TTM)
$1,365 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-125 Mln
-
ROE
0 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$3.9
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
43,029,017
10 Years Aggregate
CFO
$921.70 Mln
EBITDA
$2,458.29 Mln
Net Profit
$-892.42 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Atento S.A. - ADR
| -- | -- | -- | -- | 4,595.1 | -2.4 | -8.5 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Atento S.A. - ADR
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved... treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California. Read more
-
Exec. Chairman
Mr. Anil Bhalla
-
CEO, President & Director
Mr. Tao Fu M.B.A., M.S.
-
Headquarters
San Carlos, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Atento S.A. - ADR
What is the current share price of Atento SA - ADR Today?
The share price of Atento SA - ADR is $20.70 (NYSE) and $20.70 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Atento SA - ADR has given a return of 4595.12% in the last 3 years.
What is the current PB & PE ratio of Atento SA - ADR?
Since, TTM earnings of Atento SA - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-- |
-- |
2024 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Atento SA - ADR?
The 52-week high and low of Atento SA - ADR are Rs 24.32 and Rs 18.90 as of 31-Aug-2026.
What is the market cap of Atento SA - ADR?
Atento SA - ADR has a market capitalisation of -- as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Atento SA - ADR?
Before investing in Atento SA - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.